89631-75-4

Usage

InChI:InChI=1/C12H14N2O2S/c1-12(2,3)16-11(15)14-10-6-4-9(5-7-10)13-8-17/h4-7H,1-3H3,(H,14,15)

Upstream product

• 463-71-8 thiophosgene 
• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 

Downstream Products

• 1228281-43-3 tert-butyl-4-(5-amino-4-carbamoylthiazol-2-ylamino)phenylcarbamate 
• 797813-77-5 4-(2-((4-aminophenyl)amino)thiazol-4-yl)benzene-1,2-diol 
• 955362-52-4 1,1-dimethylethyl [4-({[(2-hydroxyethyl)amino]carbonothioyl}amino)phenyl]carbamate 
• 955362-51-3 1,1-dimethylethyl (4-{[(ethylamino)carbonothioyl]amino}phenyl)carbamate 
• 955362-50-2 1,1-dimethylethyl (4-{[(methylamino)carbonothioyl]amino}phenyl)carbamate 

Relevant academic research and scientific papers

Synthesis and in-vitro evaluation of 2-amino-4-arylthiazole as inhibitor of 3D polymerase against foot-and-mouth disease (FMD)

Foot-and-mouth disease (FMD) is a highly contagious vesicular disease of livestock caused by a highly variable RNA virus, foot-and-mouth disease virus (FMDV). One of the targets to suppress expansion of and to control FMD is 3D polymerase (FMDV 3Dpol). In this study, 2-amino-4-arylthiazole derivatives were synthesized and evaluated for their inhibitory activity against FMDV 3Dpol. Among them, compound 20i exhibited the most potent functional inhibition (IC50 = 0.39μM) of FMDV 3D polymerase and compound 24a (EC50=13.09 μM) showed more potent antiviral activity than ribavirin (EC50=1367 μM) and T1105 (EC50=347 μM) with IBRS-2 cells infected by the FMDV O/SKR/2010 strain.

TNIK INHIBITOR AND THE USE

The present invention relates to compositions and methods for the treatment of cancer patients with Traf2- and Nck-interacting kinase (TNIK) inhibitors. More particularly, the present invention relates to pharmaceutical compositions comprising TNIK inhibitor and a pharmaceutically acceptable carrier, and to methods for treating the TNIK inhibitor administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. And the present invention relates to a novel aminothiazole derivatives.